Format

Send to

Choose Destination
J Am Pharm Assoc (2003). 2019 Sep 11. pii: S1544-3191(19)30396-6. doi: 10.1016/j.japh.2019.08.002. [Epub ahead of print]

Once-daily prolonged-release tacrolimus versus twice-daily tacrolimus in liver transplantation.

Abstract

OBJECTIVE:

For patients who have received a kidney transplant, studies have shown that once-daily prolonged-release tacrolimus (TAC) has similar efficacy and safety to standard twice-daily dosing. The purpose of this study was to perform a meta-analysis to compare the effectiveness and safety of daily TAC (TAC qd) versus standard twice-daily TAC (TAC bid) administration in liver transplantation (LT).

DESIGN:

Meta-analysis.

SETTING AND PARTICIPANTS:

We systematically searched the PubMed/MEDLINE, Web of Science, and Cochrane Library databases for studies comparing outcomes of LT patients who received TAC qd versus TAC bid.

OUTCOME MEASURES:

Results were reported as odds ratios (ORs) with 95% CIs.

RESULTS:

Six studies, which included 5179 LT recipients (TAC qd = 951; TAC bid = 4228) were included in the analysis. The TAC qd group had a low 1-year graft loss rate (OR 0.70 [95% CI 0.54-0.91], P = 0.008) and lower rate of biopsy-proven acute rejection (BPAR) at 90 days (OR 0.46 [95% CI 0.24-0.89], P = 0.02) compared with the TAC bid group. There was no significant difference in 1-year mortality or the incidence of adverse events after LT between the 2 groups.

CONCLUSIONS:

Current evidence suggests that TAC qd is safe and effective for LT patients during the first year after transplantation. Longer-term follow-up studies are necessary to determine if TAC qd is safe and effective beyond the first year after LT.

PMID:
31521585
DOI:
10.1016/j.japh.2019.08.002

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center